Search the Newsreel

Hubbell (HUBB) Is Quietly Winning From AI Infrastructure Growth

Parnassus Investments, an investment management company, released the "Parnassus Core Equity Fund" second quarter of 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 16.83% in the second quarter of 2026, outperforming the S&P 500's 15.20% gain. Performance …

ALK’s tree pollen and house dust mite tablets now recommended by NICE for paediatric treatment in the UK health system

ALK Abello ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the UK's National Institute for Health and Care Excellence (NICE) has recommended the company's tree pollen tablet (ITULAZAX®) and house dust mite tablet (ACARIZAX®) for children with moderate to severe allergic rhinitis …

Bell Financial Group (ASX:BFG) Shares Look Cheap After Margin Jump

Orient Bell to host virtual investor meet on August 19

Atria Investments Inc Acquires New Position in The Campbell's Company $CPB

Atria Investments Inc. has acquired a new stake in The Campbell's Company (NASDAQ:CPB), purchasing 50,994 shares valued at approximately $1,136,000 during the second quarter. This move is part of broader institutional investor activity, with several other firms also adjusting their positions in Campbell's. The …

Assenagon Asset Management S.A. Lowers Stake in Hubbell Inc $HUBB

Assenagon Asset Management S.A. significantly reduced its stake in Hubbell Inc (NYSE:HUBB) by 88.2% in the second quarter, now holding 3,929 shares valued at $2.06 million. Despite this reduction, Hubbell reported strong financial results, with quarterly EPS of $5.52 and revenue of $1.71 billion, …

Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ...

This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Belite Bio Inc (NASDAQ:BLTE) received FDA acceptance of its New Drug Application (NDA) for Tinlarabant …

Ceribell (CBLL) director sells 13,095 shares of common stock at $23.40

Ceribell (CBLL) director Joseph Michael Taylor sold 13,095 shares of common stock at $23.40 per share on August 13, 2026, totaling $306,423. Following this transaction, Taylor directly holds 48,478 shares of Ceribell common stock. This insider sale was reported via a Form 4 filing, …

5 Must-Read Analyst Questions From Regal Rexnord’s Q2 Earnings Call

5 Must-Read Analyst Questions From Regal Rexnord's Q2 Earnings Call Regal Rexnord's second quarter saw its sales growth fall short of Wall Street's expectations, driving a significant negative market reaction. Management attributed the shortfall to persistent weakness in residential HVAC and pool markets, as …

Bella Casa Fashion & Retail Ltd. (BELLACASA) Share Price Falls 10.6% Today; Textile Micro Cap in Focus

Somi Conveyor Beltings Ltd. Share Price Today Up 19.97%

Barclays PLC (BELFA) reports 36,523 Bel Fuse Class A shares, 1.72% stake

Barclays PLC has reported an updated ownership of Bel Fuse Inc. Class A shares, holding 36,523 shares, which represents a 1.72% stake in the company as of June 30, 2026. The financial institution maintains sole voting and dispositive power over 34,107 shares and shared …

RRX|Regal Rexnord Corp|Price:172.306|Chg%:-0.594

This article provides a detailed financial overview of Regal Rexnord Corp (RRX), including its stock price, key figures, and recent performance. It highlights the company's stock score, analyst ratings, and technical analysis, showing a "Buy" consensus with a target price significantly above the current …

Belite Bio outlines February 12, 2027 PDUFA date for Tinlarebant in Stargardt disease following FDA priority review acceptance

Earnings Call Insights: Belite Bio (BLTE) Q2 2026 MANAGEMENT VIEW * Dr. Tom Lin (Chairman of the Board of Directors & CEO) framed the quarter around U.S. regulatory timing, saying, "the FDA has accepted our new drug application for Tinlarebant with priority review and …

Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips

Belite Bio reported a smaller-than-expected loss in Q2 2026, beating EPS estimates, but its stock still slipped. The company's lead candidate, tinlarebant for Stargardt disease, received priority review from the FDA, with a PDUFA date of February 12, 2027. Despite rising R&D and SG&A …

Is BellRing Brands (BRBR) Undervalued After Better Than Expected Q3 Results?

BellRing Brands (BRBR) reported better-than-expected Q3 2026 results and updated guidance, including plans for double-digit price increases on Premier products in fiscal 2027. Despite a significant share price drop over the past year, Simply Wall St suggests the stock is 23.6% undervalued compared to …

Bell Financial Group posts record 1H26 profit

Hubbell Inc. stock underperforms Thursday when compared to competitors

Hubbell Inc. (HUBB) shares fell 1.13% on Thursday, closing at $507.10, despite a generally positive trading day for the broader stock market. The S&P 500 Index rose 0.65% and the Dow Jones Industrial Average increased by 0.13%. This marks the second consecutive day of …

Belite Bio (BLTE) Is Up 12.9% After FDA Priority Review For Tinlarebant In Stargardt Disease

Belite Bio (BLTE) shares increased by 12.9% following the FDA's acceptance and Priority Review designation for its New Drug Application for tinlarebant, aimed at treating Stargardt Disease Type 1. The PDUFA target action date is set for February 12, 2027, and if approved, tinlarebant …

Belite Bio (NASDAQ:BLTE) Stock Price Down 7.2% - Should You Sell?

Belite Bio (NASDAQ:BLTE) stock declined 7.2% to $166.11 on Thursday, with trading volume below its average. Despite the drop, analysts have a "Moderate Buy" consensus rating with an average price target of $204.40. The company, a clinical-stage biotechnology firm, reported a narrower-than-expected quarterly loss …

Jefferies Just Upgraded Five Below Stock. Here's Why.

Jefferies has upgraded Five Below (FIVE) stock, raising its price target to $350 due to anticipated structural improvements and strong comparable sales growth. Analyst Randal Konik projects significant upside for the discount retailer, driven by consistent productivity gains and store network expansion. While the …

Belite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS

Janus Henderson Group (BELFA) reports 590,030 Bel Fuse Class B shares in 13G/A

Janus Henderson Group Ltd. has filed an amended Schedule 13G/A, reporting beneficial ownership of 590,030 shares of Bel Fuse Inc. Class B common stock, which represents 4.8% of the class, as of June 30, 2026. The shares are held through various affiliated asset managers …

Five Below Shares Rise After Jefferies Upgrade

Five Below (FIVE) shares rose after Jefferies upgraded the stock from Hold to Buy, increasing its price target from $210 to $350. This positive analyst action highlights renewed confidence in the specialty retailer's prospects. The article also mentions recent company news, including the opening …

Five Below Has No Business Selling a Bow Mirror This Chic for $25

Five Below is selling a new coquette-style floor-length bow mirror for just $25, offering a high-end look at a fraction of the price of similar designer versions, such as one from Pottery Barn Teen. The mirror features a sleek design with a white ribbon-style …

Jefferies upgrades Five Below to buy, sees path to TJX-like re-rating

Investing.com -- Jefferies upgraded Five Below to Buy from Hold and raised its price target to $350 from $210, arguing that investors are underestimating structural improvements at the discount retailer and focusing too heavily on the temporary boost from its popular "squishy" products. The …

AQR Capital discloses 5.22% BellRing Brands (BRBR) position in Schedule 13G/A

AQR Capital Management, LLC and its parent, AQR Capital Management Holdings, LLC, have disclosed a 5.22% beneficial ownership in BellRing Brands, Inc. (BRBR) through a Schedule 13G/A filing. As of June 30, 2026, the entities collectively beneficially own 6,067,631 shares of common stock. They …

Is Belden (BDC) Stock Outpacing Its Computer and Technology Peers This Year?

Investors interested in Computer and Technology stocks should always be looking to find the best-performing companies in the group. Has Belden (BDC) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the …

Jefferies upgrades Five Below to Buy, raises price target to $350 (FIVE:NASDAQ)

Jefferies has upgraded Five Below (FIVE) to Buy from Hold, significantly increasing its price target to $350 from $210. This upgrade is driven by structural improvements in the business and a more optimistic long-term growth outlook for the discount retailer. Following the announcement, Five …

BellRing Investor News: If You Own Stock in BellRing

The Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of BellRing Brands, Inc. (NYSE: BRBR). The firm encourages BellRing stockholders to contact them for more information regarding their rights. The Rosen Law Firm specializes in securities class …

FDA accepts Belite's tinlarebant NDA for Stargardt

Belite Bio, Inc. has received FDA acceptance for its new drug application (NDA) for tinlarebant, an investigational therapy for Stargardt disease type 1 (STGD1). The FDA has granted tinlarebant a priority review, setting the PDUFA target action date for February 12, 2027. If approved, …

The Campbell’s Company to Report Fourth Quarter and Full Year Fiscal 2026 Results on September 3, 2026

CAMDEN, N.J., August 13, 2026--(BUSINESS WIRE)--The Campbell's Company (NASDAQ:CPB) (Campbell's) announced it will report its financial results on September 3, 2026 for the fourth quarter and full year fiscal 2026 ended August 2, 2026. A press release, slide presentation, transcript and audio of pre-recorded …

Campbell’s Sets Sept. 3 Live Q&A on Fiscal 2026 Results

The Campbell's Company (NASDAQ: CPB) announced it will report its financial results for the fourth quarter and full fiscal year 2026 on September 3, 2026. A press release, slide presentation, transcript, and pre-recorded management remarks will be available at 7:15 a.m. ET, followed by …

Kimbell Royalty Partners (KRP) Stock Looks Strong On Returns But Pricey On Earnings

Belrise Industries Has Multiple Growth Bets. Is The Market Pricing In Too Much?

Belite Bio Q2 Net Loss Widens; FDA Sets PDUFA Date For Tinlarebant In February 2027

(RTTNews) - Belite Bio, Inc (BLTE), a clinical-stage drug development company, announced its financial results for the second quarter, reflecting a wider net loss. The company also provided an update on its New Drug Application (NDA) for tinlarebant for the treatment of Stargardt disease …